Palatin (PTN) announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

It's probably safe to say that weight-loss drugs aren't going anywhere any time soon. According to the most recent data, six percent of American adults, or roughly 16 million people, take such ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

Mounjaro (Terzepatide) is a dual GLP-1/GIP (Gastric Inhibitory Peptide) receptor agonist, which may offer better blood sugar control and enhanced weight loss compared to traditional GLP-1 agonists.

Advances in drug design, such as dual and triple agonists (e.g., GLP-1/gastric inhibitory peptide (GIP) and GLP-1/GIP/glucagon receptor agonists), are expanding the therapeutic impact of these ...

The data also showed that low dose MC4R agonist bremelanotide stopped the rapid weight regain seen after ending GLP-1/GIP tirzepatide ... MC4R long-acting peptide and oral small molecule compounds ...

But the drug category, initially developed for diabetes but now widely used for weight loss, has also begun to affect the food and beverage industry as consumers on GLP-1 medication — about one in ...

According to Dr Manisha Arora, as reported in The Indian Express, the drug mimics two key hormones: Glucagon-Like Peptide-1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP). These hormones play a ...